German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
German drug developer Evotec SE (NASDAQ:EVO) is reportedly consulting defense advisers following a significant drop in share price, raising concerns about the company's vulnerability to a takeover.
據報道，德國藥物開發公司Evotec SE（納斯達克:EVO）在股價大幅下跌後正在諮詢國防顧問，引發對公司易受收購的擔憂。
Multiple buyout firms are reportedly evaluating Hamburg-based Evotec as a potential acquisition target, initiating early discussions with advisers to assess the company's drug pipeline and strategic value.
據報道，多家收購公司正在評估位於漢堡的Evotec作爲潛在的收購目標，與顧問們進行初步討論，評估該公司的藥物管線和戰略價值。
Evotec's shares surged. The spike follows a year-to-date decline of over 60%, with the stock recently hitting its lowest since March 2017. The drop came after Intron Health analysts downgraded the stock from "buy" to "sell."
Evotec的股票大幅上漲，而之前的股價下跌了超過60％，股票最近一次跌至2017年3月以來的最低點。此次下跌是在Intron Health分析師將該股票評級從“買入”降至“賣出”之後發生的。
Bloomberg noted, citing sources, that despite the market activity, no formal approaches have been made, and it is expected to be several months before any concrete interest emerges.
彭博社援引消息人士稱，儘管有市場活動，但尚未進行任何正式的接觸，並預計需要幾個月時間才會出現任何具體的興趣。
The transition in leadership at Evotec adds another layer of complexity. In January, the company announced that CEO Werner Lanthaler would step down early for personal reasons. Subsequently, it was disclosed that Lanthaler had failed to report his stock trades on time, though this was unrelated to his departure.
Evotec領導層的變動增加了更多的複雜性。今年1月，該公司宣佈首席執行官Werner Lanthaler因個人原因提前辭職。隨後，披露Lanthaler未能及時報告他的股票交易，但這與他的離職無關。
Christian Wojczewski, the incoming CEO, will assume his role next month and is expected to review the situation before making any strategic decisions.
即將上任的首席執行官Christian Wojczewski預計將在下個月就目前的情況進行審查，之後再作出任何戰略決策。
Major moves will require backing from Evotec's key shareholders, Novo Holdings A/S and Mubadala Investment Co. Novo Holdings is the parent company of drugmaker Novo Nordisk A/S (NYSE:NVO), indicating significant industry connections.
重大舉措將需要Evotec的主要股東諾沃控股和穆巴達拉投資有限公司的支持。諾沃控股是藥廠諾和諾德（紐交所:NVO）的母公司，這表明有重要的行業聯繫。
Evotec has established partnerships with major healthcare companies such as Bristol-Myers Squibb Co. (NYSE:BMY) and Eli Lilly & Co. (NYSE:LLY), focusing on developing treatments for chronic kidney disease, neuroscience, and metabolic disorders.
Evotec與布里斯托-邁爾斯斯奎布公司（紐交所:BMY）和禮來公司（紐交所:LLY）等主要醫療保健公司建立了合作伙伴關係，專注於開發治療慢性腎臟疾病、神經科學和代謝性疾病的藥物。
Most recently, Evotec said it made important scientific progress in its neuroscience collaboration with Bristol Myers Squibb, which triggered a research payment of $20 million to Evotec.
最近，Evotec表示，其與布里斯托-邁爾斯斯奎布的神經科學合作取得了重要的科學進展，引發了對Evotec的價值2000萬美元的研究付款。
Price Action: EVO shares are up 9.09% at $4.44 at last check Thursday.
價格走勢：EVO股票在週四的最後一次檢查時上漲9.09％，至4.44美元。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。